This story originally ran on Sept. 15.

Cell Biosciences last week announced it had entered into a definitive agreement to acquire Alpha Innotech for $20 million in a deal that further accelerates Cell Biosciences' transition to a full commercial operation.

Under the terms of the deal, anticipated to close in 60 days, Cell Biosciences would pay $1.50 for each share of Alpha Innotech stock for a total of $17.9 million in cash. It also would assume $2.1 million of outstanding debt from Alpha Innotech.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.